The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Transaction #3381 · Form 4 · 0001864159-25-000003

Janux Therapeutics, Inc. · Exercise / conversion · Common Stock

Janux Therapeutics, Inc. · Transacted October 28, 2025 · Filed October 30, 2025

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for Janux Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 28, 2025. The reported quantity was 6,666. The filing date is October 30, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0001817713
Security type
Non-derivative
Acquisition type
Exercise / conversion · Code M
Quantity acquired
6,666
Reported price
10.59
Reference value
70,592.94
Currency
Currency not specified
Ownership
Direct
Holdings after transaction
98,804
Ownership description
Not reported
SEC acceptance time
Oct 30, 2025, 8:00 PM EDT
10b5-1 indication
Indicated in filing

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

JANX · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
F2
The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3
Immediately exercisable.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.